ERS Genomics announces agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents 

DUBLIN, Ireland, and Milpitas, CA USA, 15th Septemer 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents and genetically modified cell lines and organisms.

Applied StemCell is a fast growing California based biotech company with a goal of advancing gene editing and stem cell innovation worldwide. Applied StemCell offers a wide variety of preclinical research services including cell and animal model generation, antibody discovery, and preclinical assay services to support cell/gene product development.

“Applied StemCell has been a leading stem cell company I have followed for many years," stated Eric Rhodes, CEO of ERS Genomics. “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."

“We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,” stated Ruby Tsai, CEO of Applied StemCell.

Financial details of the agreement are not disclosed.

About ERS Genomics www.ersgenomics.com

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com

About Applied StemCell

Applied StemCell, Inc. is a fast-growing biotechnology company with 12 years of experience in genome editing and stem cell technologies. Our mission is to advance genome editing technology innovation to enable in vivo/in vitro preclinical studies as well as serving as a CRO for gene and cell therapy projects. More information can be found at www.appliedstemcell.com.